Eli Lilly's Retevmo Cuts Lung Cancer Recurrence Risk 60% in Late-Stage Trial
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
eli-lillyretevmo
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Eli Lilly announced on 31 May 2026 that its RET inhibitor Retevmo (selpercatinib) met its primary endpoint in the Phase 3 LIBRETTO-004 trial, demonstrating a statistically significant reduction in the risk of disease recurrence in patients with early-stage RET-mutated non-small cell lung cancer. The company stated the drug cut the risk of recurrence or death by approximately 60% compared to placebo in the adjuvant setting, a magnitude of benefit that could expand the drug's addressable patient population by tens of thousands annually. Full data will be presented at an upcoming medical conference and submitted to global regulators for a supplemental approval.
The result arrives amid intensifying competition in the lucrative lung cancer adjuvant market, where Merck & Co.’s Keytruda dominates. The last major shift occurred in October 2023, when Keytruda showed a 41% reduction in the risk of death for certain early-stage NSCLC patients, solidifying a multi-billion dollar franchise. The current oncology landscape is characterized by a push into earlier lines of treatment, where curative intent offers longer treatment durations and higher revenue potential per patient. The catalyst for Lilly’s trial readout now is the maturation of event-free survival data following the 2020 accelerated approval of Retevmo for later-line metastatic RET-mutant cancers, a $400-500 million annual segment. Success in adjuvant therapy represents a strategic imperative for Lilly to maximize the value of its 2023 Loxo Oncology acquisition.
The reported 60% reduction in risk of recurrence or death represents a hazard ratio of approximately 0.40. The LIBRETTO-004 trial enrolled an estimated 170 patients with Stage IB-IIIA RET-mutant NSCLC following tumor resection. The adjuvant treatment market for early NSCLC is projected to exceed $25 billion globally by 2030, with Keytruda commanding a dominant share. Retevmo’s current sales are anchored in metastatic settings; a successful adjuvant label expansion could increase its peak sales estimate from ~$1.5 billion to over $3 billion. For comparison, AstraZeneca’s Tagrisso, an EGFR inhibitor used in the adjuvant setting, generated $5.8 billion in 2025, demonstrating the revenue scale of effectively moving a targeted therapy earlier. The 60% efficacy signal exceeds the 44-57% disease-free survival benefit range observed for most checkpoint inhibitors in similar early-stage settings, though cross-trial comparisons are limited.
The primary beneficiary is Eli Lilly (LLY), which could see its oncology portfolio revenue diversify beyond diabetes and obesity drugs. A successful launch would pressure Merck (MRK) and Bristol-Myers Squibb (BMY), whose checkpoint inhibitors Opdivo and Keytruda are used broadly in NSCLC but lack specific activity against RET mutations. Diagnostic companies with comprehensive genomic profiling tests, like Guardant Health (GH) and Foundation Medicine (a Roche subsidiary), stand to gain from increased RET testing in early-stage patients. The key risk is the unknown maturity of the overall survival data, which remains a secondary endpoint; disease-free survival benefits do not always translate into definitive survival advantages. Investment flow is likely rotating into Lilly and other companies with targeted adjuvant pipelines, while short interest may build in smaller biotechs developing competing RET inhibitors like Blueprint Medicines’ pralsetinib, which now faces a significant efficacy benchmark.
The next catalyst is the presentation of detailed LIBRETTO-004 data at a major oncology conference, likely the American Society of Clinical Oncology (ASCO) meeting in June 2026 or the European Society for Medical Oncology (ESMO) Congress in September 2026. Investors should monitor the supplemental New Drug Application (sNDA) submission to the U.S. FDA, expected in Q4 2026, with a potential Priority Review decision within 60 days of submission. Key levels to watch are the overall survival data trend and the complete response rate from the trial, which will inform commercial uptake. Regulatory decisions in the EU and Japan will follow in 2027. The performance of Blueprint Medicines’ (BPMC) competing ACRIB trial for pralsetinib in the same setting, with data expected in 2027, will determine if Retevmo faces near-term branded competition.
A RET (Rearranged during Transfection) gene alteration is a specific genomic driver found in approximately 1-2% of patients with non-small cell lung cancer. It causes uncontrolled cell growth. RET inhibitors like Retevmo are designed to block the abnormal protein produced by this mutation, offering a targeted treatment option distinct from chemotherapy or immunotherapy. Identifying this mutation requires biomarker testing of tumor tissue or blood.
Adjuvant therapy is given after primary surgery with curative intent to eliminate any remaining microscopic cancer cells and reduce the risk of the cancer returning. Metastatic treatment is for cancer that has already spread to other parts of the body and is typically not curable. Moving a drug like Retevmo into the adjuvant setting significantly expands its use from a later-line, palliative treatment to an earlier, potentially curative one, impacting both patient outcomes and the drug’s commercial potential.
Beyond NSCLC, Retevmo is already approved for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. Clinical trials are ongoing in other RET-altered solid tumors, including colorectal, pancreatic, and breast cancers. The success in lung cancer adjuvant therapy validates the drug’s potency and could accelerate its development in these other tumor types, further broadening Eli Lilly’s oncology footprint. For more on targeted therapy development, visit https://fazen.markets/en.
Lilly’s Retevmo has set a new high-efficacy benchmark in adjuvant RET+ lung cancer, positioning it for a major market expansion and intensified competitive pressure on broad-based immunotherapies.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.